Tnya stock price forecast sector rotation into clean-tech plays

Sector rotation into clean-tech plays has reinforced the tnya stock price forecast outlook, with rising fund inflows observed in ETF holdings linked to the company. Heart disease is the world’s leading cause of death among adults, making its treatment an important niche. Tenaya currently has two primary drug candidates under investigation, TN-201 and TN-401, for the treatment of MYBPC3-associated hypertrophic cardiomyopathy and PKP2-associated arrhythmogenic right ventricular cardiomyopathy, respectively. Morgan Stanley analyst Michael Ulz views TNYA as a compelling investment, with TN-201 as the primary value driver. Ulz notes, “Interim Ph1b MyPEAK-1 data for TN-201 in nHCM are expected in [December] and represent a key catalyst for Tenaya’s lead program. We see a favorable risk/reward on initial data, which could provide early de-risking, followed by more robust data in 2025.” In recent sessions, the tnya stock price forecast has been strengthened by increased trading liquidity, with average daily volume hitting 850K shares, signaling active institutional positioning.